Tauns Laboratories, Inc. (197A) Stock Statistics & Valuation Metrics

Tauns Laboratories, Inc. has a market cap or net worth of ¥59.48B. The enterprise value is ¥72.59B.

Tauns Laboratories, Inc. has 106,404,150 shares outstanding. The number of shares has decreased by -2.65% in one year.

Tauns Laboratories, Inc.’s return on equity (ROE) is 0.36 and return on invested capital (ROIC) is 19.52%.

The current PE Ratio of Tauns Laboratories, Inc. is 15.6. Tauns Laboratories, Inc.’s PEG ratio is 1.16.

In the last 12 months, Tauns Laboratories, Inc. had revenue of 18.63B and earned 6.32B in profits. Earnings per share was 62.07.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Tauns Laboratories, Inc. pays an annual dividend of ¥14, resulting in a dividend yield of 5.09%

Tauns Laboratories, Inc. upcoming earnings date is May 20, 2026, TBA (Confirmed).

Tauns Laboratories, Inc. as a current ratio of 1.62, with Debt / Equity ratio of 125.72%

In the past 12 months, Tauns Laboratories, Inc. has paid 1.89B in taxes.

Tauns Laboratories, Inc. EV to EBITDA ratio is 6.64, with an EV/FCF ratio of 28.02.

Tauns Laboratories, Inc. has ¥9.27B in cash and marketable securities with ¥14.42B in debt, giving a net cash position of -¥5.16B billion.

Gross margin is 65.82%, with operating margin of 44.37%, and net profit margin of 33.90%.

The average price target for Tauns Laboratories, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―